Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease-Reference-Cited by-同舟云学术

Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease

Published:2013-11 Issue:6 Volume:19 Page:1025-1034
ISSN:1530-891X
Container-title:Endocrine Practice
language:en
Short-container-title:Endocrine Practice

Author:

Ramirez German,Morrison Anthony D.,Bittle Polly A.

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://aace.metapress.com/index/136173844H6838GH.pdf

Reference77 articles.

1. Pharmacology of dipeptidyl pepti-dase-4 inhibitors: similarities and differences;Baetta;Drugs,2011

2. Treatment of patients with diabetes with GLP-1 analogues or DPP-4-inhibitors: a hot topic for cardiologists?;Jax;Clin Res Cardiol,2009

3. Comparative effectiveness of incident oral antidiabetic drugs on kidney function;Hung;Kidney Int,2012

4. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice;Abe;Curr Drug Metab,2011

5. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease;Reilly;Semin Dial,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials;Diabetes, Metabolic Syndrome and Obesity;2024-03

2. Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin;Diabetes, Obesity and Metabolism;2023-04-03

3. DPP4 Inhibitor-Induced Bullous Pemphigoid in Patients with Diabetes and Chronic Kidney Disease: Clinical Case Series;Nephron;2022-07-18

4. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists;Journal of Clinical Medicine;2020-03-30

5. Renal outcomes with dipeptidyl peptidase-4 inhibitors;Diabetes & Metabolism;2018-03